Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LA JOLLA PHARMACEUTICAL COLJPC · Entity 124310 | Director · President, CEO & Secretary | April 15, 2019 | April 17, 2019 |
| Odonate Therapeutics, Inc.ODT · Entity 132524 | Director | September 19, 2019 | September 23, 2019 |
| REVELATION BIOSCIENCES, INC.REVB · Entity 8359 | Director | February 11, 2025 | February 13, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LA JOLLA PHARMACEUTICAL CO
Report date April 15, 2019 · Filed April 17, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,263,895 |
Reported balance
After 2019-04-15 transaction · row 1
1 source rowRow 1 · 2019-04-15 · Grant · Acquired 2 · Balance 1,263,895 F1: These shares were acquired on 04/15/2019 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.16 · Expires 2029-04-15 | Direct | 2 |
Reported balance
After 2019-04-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-04-15 · Grant · Acquired 2 · Balance 2 F2: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. |
| Common StockSEC Table I · non-derivative | IndirectBy children | 22,000 |
Reported balance
Holding disclosure · report date 2019-04-15 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 22,000 |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were acquired on 04/15/2019 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
F2: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years.
Odonate Therapeutics, Inc.
Report date September 19, 2019 · Filed September 23, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 151,291 |
Ending reported balance
After 2019-09-19 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2019-09-19 · Exercise / conversion · Acquired 77,331 · Balance 77,331 F1: The Reporting Person received 77,331 shares of common stock on exercise of incentive units, pursuant to the terms of the Odonate Management Holdings, LLC Equity Incentive Plan. Row 2 · 2019-09-19 · Exercise / conversion · Acquired 73,960 · Balance 151,291 F2: The Reporting Person received 73,960 shares of common stock on exercise of incentive units, pursuant to the terms of the Odonate Management Holdings, LLC Equity Incentive Plan. |
| Incentive UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.54 | Direct | 43,225 |
Reported balance
After 2019-09-19 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-09-19 · Exercise / conversion · Disposed 78,821 · Balance 43,225 F3: The incentive units vested with respect to 25% of the underlying shares on 12/30/2017, with the remaining shares vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer through each vesting date. F4: The incentive units do not expire. |
| Incentive UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.54 | Direct | 49,391 |
Reported balance
After 2019-09-19 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-09-19 · Exercise / conversion · Disposed 75,385 · Balance 49,391 F5: The incentive units vested with respect to 25% of the underlying shares on 3/2/2018, with the remaining shares vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer through each vesting date. F4: The incentive units do not expire. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person received 77,331 shares of common stock on exercise of incentive units, pursuant to the terms of the Odonate Management Holdings, LLC Equity Incentive Plan.
F2: The Reporting Person received 73,960 shares of common stock on exercise of incentive units, pursuant to the terms of the Odonate Management Holdings, LLC Equity Incentive Plan.
F3: The incentive units vested with respect to 25% of the underlying shares on 12/30/2017, with the remaining shares vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer through each vesting date.
F4: The incentive units do not expire.
F5: The incentive units vested with respect to 25% of the underlying shares on 3/2/2018, with the remaining shares vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer through each vesting date.
REVELATION BIOSCIENCES, INC.
Report date February 11, 2025 · Filed February 13, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 268 |
Reported balance
After 2025-02-11 transaction · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · 2025-02-11 · Grant · Acquired 181 · Balance 268 F2: Restricted Stock Grant under the 2021 Equity Incentive Plan. Vests 100% on date of grant. F1: Shares are held by George Tidmarsh, Trustee George Francis Tidmarsh 2021 Irrevocable Trust |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 87 |
Reported balance
Holding disclosure · report date 2025-02-11 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 87 F1: Shares are held by George Tidmarsh, Trustee George Francis Tidmarsh 2021 Irrevocable Trust |
Filing footnotes · ownership attribution and instrument terms
F1: Shares are held by George Tidmarsh, Trustee George Francis Tidmarsh 2021 Irrevocable Trust
F2: Restricted Stock Grant under the 2021 Equity Incentive Plan. Vests 100% on date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 30, 2018 Filed Dec 3, 2018 21:56 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 100 | $12.30 | $1,229.95 |
DisclosureSEC source: 0000920465-18-000062 · wf-form4_154389217444229.xml · nonDerivative · entry 1 TIDMARSH GEORGE F · CIK 0001287235 · Director · President, CEO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,281,060 F1 · kind: These shares were acquired on 11/30/2018 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| November 15, 2018 Filed Nov 19, 2018 17:06 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 97 | $0.00 Strike: $14.90 | $0.00 |
DisclosureSEC source: 0000920465-18-000059 · wf-form4_154266517918605.xml · derivative · entry 3 TIDMARSH GEORGE F · CIK 0001287235 · Director · President, CEO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97 Underlying: Common Stock · 97 shares Expires 2028-11-15 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| November 15, 2018 Filed Nov 19, 2018 17:06 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 97 | $12.67 | $1,228.51 |
DisclosureSEC source: 0000920465-18-000059 · wf-form4_154266517918605.xml · nonDerivative · entry 1 TIDMARSH GEORGE F · CIK 0001287235 · Director · President, CEO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,280,960 F1 · kind: These shares were acquired on 11/15/2018 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| October 31, 2018 Filed Nov 1, 2018 20:41 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 89 | $0.00 Strike: $16.30 | $0.00 |
DisclosureSEC source: 0000920465-18-000051 · wf-form4_154111927037311.xml · derivative · entry 3 TIDMARSH GEORGE F · CIK 0001287235 · Director · President, CEO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89 Underlying: Common Stock · 89 shares Expires 2028-10-31 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| October 31, 2018 Filed Nov 1, 2018 20:41 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 89 | $13.86 | $1,233.10 |
DisclosureSEC source: 0000920465-18-000051 · wf-form4_154111927037311.xml · nonDerivative · entry 1 TIDMARSH GEORGE F · CIK 0001287235 · Director · President, CEO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,280,863 F1 · kind: These shares were acquired on 10/31/2018 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| October 15, 2018 Filed Oct 15, 2018 20:52 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 88 | $0.00 Strike: $16.25 | $0.00 |
DisclosureSEC source: 0000920465-18-000040 · wf-form4_153965110602270.xml · derivative · entry 3 TIDMARSH GEORGE F · CIK 0001287235 · Director · President, CEO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88 Underlying: Common Stock · 88 shares Expires 2028-10-15 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| October 15, 2018 Filed Oct 15, 2018 20:52 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 88 | $13.81 | $1,215.28 |
DisclosureSEC source: 0000920465-18-000040 · wf-form4_153965110602270.xml · nonDerivative · entry 1 TIDMARSH GEORGE F · CIK 0001287235 · Director · President, CEO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,280,774 F1 · kind: These shares were acquired on 10/15/2018 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| June 08, 2018 Filed Feb 13, 2019 18:25 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GiftCommon Stock | 900 | $0.00 | $0.00 |
DisclosureSEC source: 0000920465-19-000032 · wf-form5_155010030902407.xml · nonDerivative · entry 5 TIDMARSH GEORGE F · CIK 0001287235 · Director · President, CEO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,263,104 Read SEC document |
| June 08, 2018 Filed Feb 13, 2019 18:25 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GiftCommon Stock | 900 | $0.00 | $0.00 |
DisclosureSEC source: 0000920465-19-000032 · wf-form5_155010030902407.xml · nonDerivative · entry 4 TIDMARSH GEORGE F · CIK 0001287235 · Director · President, CEO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,264,004 Read SEC document |
| June 08, 2018 Filed Feb 13, 2019 18:25 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GiftCommon Stock | 900 | $0.00 | $0.00 |
DisclosureSEC source: 0000920465-19-000032 · wf-form5_155010030902407.xml · nonDerivative · entry 3 TIDMARSH GEORGE F · CIK 0001287235 · Director · President, CEO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,264,904 Read SEC document |
| June 08, 2018 Filed Feb 13, 2019 18:25 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GiftCommon Stock | 900 | $0.00 | $0.00 |
DisclosureSEC source: 0000920465-19-000032 · wf-form5_155010030902407.xml · nonDerivative · entry 2 TIDMARSH GEORGE F · CIK 0001287235 · Director · President, CEO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,265,804 Read SEC document |
| June 08, 2018 Filed Feb 13, 2019 18:25 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GiftCommon Stock | 17,742 | $0.00 | $0.00 |
DisclosureSEC source: 0000920465-19-000032 · wf-form5_155010030902407.xml · nonDerivative · entry 1 TIDMARSH GEORGE F · CIK 0001287235 · Director · President, CEO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,266,704 Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 20:57 UTC | Odonate Therapeutics, Inc. ODT · Entity 132524 | GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $24.73 | $0.00 |
DisclosureSEC source: 0001209191-18-002272 · doc4.xml · derivative · entry 1 TIDMARSH GEORGE F · CIK 0001287235 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2028-01-02 F1 · derivative.exercise_date: This option represents a right to purchase a total of 12,500 shares of the Issuer's Common Stock, which shall be fully vested and exercisable on January 2, 2019. Read SEC document |
| December 27, 2017 Filed Dec 29, 2017 17:04 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $32.47 | $0.00 |
DisclosureSEC source: 0000920465-17-000089 · wf-form4_151458503165979.xml · derivative · entry 1 TIDMARSH GEORGE F · CIK 0001287235 · Director · President, CEO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-12-27 F1 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| December 11, 2017 Filed Dec 13, 2017 21:05 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 183,000 | $0.00 Strike: $28.10 | $0.00 |
DisclosureSEC source: 0000920465-17-000078 · wf-form4_151321713894213.xml · derivative · entry 1 TIDMARSH GEORGE F · CIK 0001287235 · Director · President, CEO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,000 Underlying: Common Stock · 183,000 shares Expires 2027-12-11 F1 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of the grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| October 05, 2017 Filed Feb 14, 2018 21:52 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GiftCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-004076 · doc5.xml · nonDerivative · entry 2 TIDMARSH GEORGE F · CIK 0001287235 · Director · President, CEO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,282,686 F2 · kind: Represents a bona fide gift to a not-for-profit charitable entity Read SEC document |
| October 02, 2017 Filed Feb 14, 2018 21:52 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GiftCommon Stock | 71,400 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-004076 · doc5.xml · nonDerivative · entry 1 TIDMARSH GEORGE F · CIK 0001287235 · Director · President, CEO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,282,686 F1 · kind: Represents bona fide gifts to two not-for-profit charitable entities Read SEC document |
| March 03, 2017 Filed Mar 6, 2017 16:02 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | PurchaseCommon Stock | 1,000 | $34.15 | $34,150.00 |
DisclosureSEC source: 0000920465-17-000037 · wf-form4_148883412602740.xml · nonDerivative · entry 2 TIDMARSH GEORGE F · CIK 0001287235 · Director · President, CEO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,354,086 Read SEC document |
| March 02, 2017 Filed Mar 6, 2017 16:02 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | PurchaseCommon Stock | 2,000 | $34.18 | $68,354.60 |
DisclosureSEC source: 0000920465-17-000037 · wf-form4_148883412602740.xml · nonDerivative · entry 1 TIDMARSH GEORGE F · CIK 0001287235 · Director · President, CEO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,353,086 Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 18:24 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 214,700 | $0.00 Strike: $19.19 | $0.00 |
DisclosureSEC source: 0000920465-17-000019 · wf-form4_148374502762395.xml · derivative · entry 1 TIDMARSH GEORGE F · CIK 0001287235 · Director · President, CEO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,700 Underlying: Common Stock · 214,700 shares Expires 2027-01-04 F1 · derivative.exercise_date: This option represents a right to purchase a total of 214,700 shares of the Issuer's Common Stock one quarter of which shall be fully vested and exercisable on January 4, 2018, with the remaining 161,025 shares vesting monthly thereafter over the next three years. Read SEC document |
| December 28, 2016 Filed Dec 30, 2016 21:46 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GiftCommon Stock | 74,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-16-036468 · doc4.xml · nonDerivative · entry 1 TIDMARSH GEORGE F · CIK 0001287235 · Director · President, CEO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,351,086 F1 · kind: Represents bona fide gifts to two not-for-profit public charitable entities. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.